Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer

Urology

Volumn 54, Issue 2, 1999, Pages 225-228

  Maeda, Hiroshi ^a   Arai, Yoichi ^a   Aoki, Yoshitaka ^a   Okubo, Kazutoshi ^a   Okada, Takashi ^a   Maekawa, Shinya ^a  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0032801173     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00149-1     Document Type: Article

References (15)

1. Catalona W.J., Beiser J.A., Smith D.S. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol. 158:1997;2162-2167.
2. Arai Y., Maeda H., Ishitoya S., et al. Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol. 158:1997;861-864.
3. Maeda H., Arai Y., Ishitoya S., et al. PSA adjusted for the transition zone volume as an indicator of prostate cancer. J Urol. 158:1997;2193-2196.
4. Lilja H. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol Clin North Am. 20:1993;681-686.
5. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
6. Maeda H., Arai Y., Okubo K., et al. Value of the free-to-total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients. Int J Urol. 5:1998;343-348.
7. Chichibu K., Kuroe K., Hashimoto C., et al. Specific quantification of gamma-seminoprotein-alpha 1 antichymotrypsin complex in serum by monoclonal antibody-based enzyme immunoassay. Jpn J Clin Pathol (Rinsho Byori). 43:1995;1153-1158.
8. 1-antichymotrypsin complex values in diagnosis of prostate cancer a cooperative study . Int J Urol. 6:1998;48-54.
9. Djavan B., Zlotta A.R., Byttebier G., et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol. 160:1998;411-418.
10. Lin D.W., Gold M.H., Ransom S., et al. Transition zone prostate specific antigen density lack of use in prediction of prostatic carcinoma . J Urol. 160:1998;77-81.
11. Brawer M.K., Meyer G.E., Letran J.L., et al. Measurement of complexed PSA improved specificity for early detection of prostate cancer. Urology. 52:1998;372-378.
12. Kurita Y., Ushiyama T., Suzuki K., et al. PSA value adjusted for the transition zone volume in the diagnosis of prostate cancer. Int J Urol. 3:1996;367-372.
13. Oesterling J.E., Kumamoto Y., Tsukamoto T., et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men lower values than for similarly aged white men . Br J Urol. 75:1995;347-353.
14. Stroumbakis N., Cookson M.S., Reuter V.E., et al. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology. 49:1997;113-118.
15. Karakiewicz P.I., Bazinet M., Aprikian A.G., et al. Outcome of sextant biopsy according to gland volume. Urology. 49:1997;55-59.